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Yeast exonuclease 1 (Exo1) is induced during meiosis
and plays an important role in DNA homologous recom-
bination and mismatch correction pathways. The hu-
man homolog, an 803-amino acid protein, shares 55%
similarity to the yeast Exo1. In this report, we show that
the enzyme functionally complements Saccharomyces
cerevisiae Exo1 in recombination of direct repeat DNA
fragments, UV resistance, and mutation avoidance by in
vivo assays. Furthermore, the human enzyme sup-
presses the conditional lethality of a rad27D mutant,
symptomatic of defective RNA primer removal. The pu-
rified recombinant enzyme not only displays 5*-3* dou-
ble strand DNA exonuclease activity, but also shows an
RNase H activity. This result indicates a back-up func-
tion of exonuclease 1 to flap endonuclease-1 in RNA
primer removal during lagging strand DNA synthesis.
Mutations cause genomic instability and gene dysfunction,
many of which affect cell growth and lead to tumorigenesis.
Fortunately, in normal cells, mutation rate is low due to the
existence of different DNA repair systems such as mismatch,
excision, and recombinational DNA repair pathways. In hu-
mans, DNA mutation accumulation is a critical step in carci-
nogenesis. Dysfunctional mutations of DNA mismatch repair
genes such as MSH2, MLH1, and PMS2, are the main cause of
the hereditary non-polyposis colorectal cancer (1–6). A portion
of sporadic cancers is due to acquired mutations in mismatch
repair genes as well (7). Mutations of genes encoding nucleotide
excision repair proteins including XPG nuclease are linked to
xeroderma pigmentosum (8–17).
Nucleases play important roles in several pathways includ-
ing DNA replication, repair, and recombination. DNA frag-
ments containing a lesion are removed by the combined efforts
of a helicase and a nuclease. For instance, in the DNA mis-
match repair of E. coli, exonucleases, exo I (39-59 excision) and
exo VII or Rec J (59-39 excision) are responsible for the bi-
directional removal of DNA fragments containing mismatched
lesions (18, 19). For DNA recombination or repair of double
strand DNA breaks through recombination, an important step
is to generate a 39 single-stranded terminus for strand inva-
sion. This step is accomplished by 59-39 exonucleases (20–22).
During DNA replication the removal of RNA primers in the
lagging strand also requires 59-39 nuclease activity (23). In E.
coli and other bacteria, the removal of RNA primers is per-
formed by the 59-39 exonuclease activity of DNA polymerase I
(24–27). The polA ex1 mutant, defective in 59-39 exonuclease
activity, exhibits retarded joining of nascent DNA fragments.
In eukaryotes, DNA polymerases lack an intrinsic 59-nuclease.
Removal of RNA primers is carried out by an independent
enzyme, Rad27/FEN-1 nuclease, with both flap endonuclease
and 59-39exonuclease activities (28–38). Disruption of the flap
endonuclease gene RAD27 in the yeast Saccharomyces cerevi-
siae resulted in DNA replication defective symptom including
the conditional lethality (39–42). Survival of the null mutant
at 30 °C suggests that other enzymes with 59-39 exonuclease
activity could back up the function of Rad27/FEN-1 in DNA
replication (29, 43).
A 59-39 exonuclease, called exonuclease 1 (Exo1) in Schizo-
saccharomyces pombe and S. cerevisiae and Tosca in Drosophila
melanogaster, has recently been identified and partially char-
acterized (44–48). The enzyme is a non-processive double-
stranded DNA nuclease (44). Both the messenger RNA level
and enzyme activity were dramatically induced during meiosis
in S. pombe (44, 45). In D. melanogaster, the gene is specifically
expressed in the early embryogenesis and female germline (46).
The S. cerevisiae and human exonucleases 1 interact with
mismatch repair protein Msh2 as demonstrated by the two-
hybrid system and immuno-coprecipitation (48–50). Disrup-
tion of EXO1 increased mutation rate in both S. pombe and S.
cerevisiae cells, indicating that EXO1 is a mutator gene (45,
48). Detailed analysis of the mutational spectrum of the exo1D
cells suggested a role for the encoded protein in mismatch
correction, most likely during homologous recombination. In
addition, deletion of yEXO1 significantly decreased both mei-
otic and mitotic recombination rates (45, 47, 48). One specula-
tion is that the nuclease plays a role creating 39 single-stranded
complementary tails, thereby promoting joint molecule forma-
tion. Moreover, the null mutant displays a minor UV sensitiv-
ity unlikely due to a nucleotide excision repair deficiency but
may be due to a defective DNA replication by-pass pathway
(51). These findings indicate that the Exo1 homologs function
as 59-39 exonucleases in mutation prevention via multiple DNA
metabolic pathways. More recently, human homolog of the
exonuclease 1 has been identified and the gene was named
HEX1 (52). It is specifically expressed in fetal liver and adult
bone marrow, suggesting that the enzyme may operate prom-
inently in processes specific to hemopoietic stem cell develop-
ment. The gene has been mapped to 1q43, a region lost in some
cases of acute leukemia and in several solid tumors (49, 52).
Human and S. cerevisiae exonuclease sequences have high
similarity. This similarity leads us to predict that functions of
these two enzymes are also similar and the human gene may
complement the Exo1 functions in yeast. In addition, when
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Szankasi and Smith (45) identified the S. pombe gene
(SpEXO1), they noticed that the encoded protein displays sig-
nificant similarity to the proteins of rad13 (XPG/Rad2) and
rad2 (FEN-1/Rad27) nuclease families. However, the similari-
ties were limited to regions of N-terminal putative nuclease
domains and the major part at C terminus was largely diver-
gent (45). We hypothesize that the human exonuclease 1 may
further complement the Rad27 nuclease functions in RNA
primer removal during lagging strand DNA synthesis based on
the observations of the sequence conservation between these
two proteins, their enzymological properties, and phenotypical
characteristics (i.e. conditional lethality) of the rad27 null mu-
tants. Our in vitro and in vivo data demonstrate that the
human exonuclease can functionally complement the yeast ho-
mologues (yExo 1 and yRad27) in recombination, UV resist-
ance, RNA primer removal during the Okazaki fragment proc-
essing, and mutation avoidance.
EXPERIMENTAL PROCEDURES
Materials—A cDNA clone (number 843301) harboring a putative
human exonuclease 1 was obtained from ATCC (Manassas, VA). Oligo-
nucleotides used in this study were synthesized in the City of Hope
Cancer Center core facility. The vector pET-28a and E. coli strains
BL21 and BL21 (DE3) were from Novagen (Madison, WI) and E. coli
strain XL2 blue and pBSK vector were from Stratagene (La Jolla, CA).
Yeast expression vector pDB20 was a gift from D. Becker, California
Institute of Technology. Restriction enzymes were obtained from New
England Biolabs (Beverly, MA). Yeast culture media including YPD,
synthetic complete (SC), minimal sporulation, and synthetic dextrose
minimal (SD) media were prepared according to Sherman et al. (53).
Amino acids and all other medium components and chemicals were
purchased from Sigma. Isopropyl b-D-thiogalactoside was purchased
from Roche Molecular Biochemicals (Indianapolis, IN).
Yeast Gene Disruption—All of the yeast strains constructed and used
in this study are listed in Table I. For construction of the EXO1 null
mutant strain, the EXO1 gene was amplified by PCR1 using primers
with HindIII and NcoI sites (exolpl (AGAAAGCCATGGGTATC-
CAAGGT) and exolp2 (CTCCGAAAGCTTTCAGTGATGATGGTG-
GTGGTGTTTACCTTTATAAACAAATTGGGAA) and cloned into the
vector pET-28b (Novagen). The marker gene URA3 was obtained from
plasmid YEp24 and inserted into PstI sites, replacing the EXO1 coding
sequence between positions 170 and 828. The fragment containing the
exo1::URA3 construct was removed from the plasmid with restriction
enzymes XbaI and NotI. The exo1::URA3 fragment was then trans-
formed into yeast strains W1021-7c and W1089-6c (Table I). Ura31
transformants were analyzed by PCR using primers exolp3 (CGAA-
CAAACTGAAAGGCGTAG) and exolp4 (GTCTTGAGGCATTTCGAC-
GAG) and Southern blotting to verify disruption of EXO1. The exo1
rad51 double mutant was obtained by crossing exo1 (FDAB15D) with
rad51 (U687, a gift from Adam Bailis, City of Hope). RAD27 gene was
deleted by transforming the wild type strains W1021-7c and W1089-6c
with a PCR-generated DNA fragment. The PCR product was generated
using YEp13 containing LEU2 marker gene as a template and two
primers KNRTH1 (CATCGATGAAAAGCGTTGACAGCATACATTGG-
AAAGAAATAGGAAACGGACACCGGAAGTTAACTGTGGGAATACT-
CA) and KNRTH2 (AGCTGTTCCTTTGTCTTAGGCACCACTTGGAA-
GAACCCATCTAACCTACCCTGACTACGTCGTAAGGCCGTTT) (und-
erlined sequences were designed to amplify LEU2 marker gene, the
remaining sequences are from RAD27). Another pair of the primers was
1 The abbreviations used are: PCR, polymerase chain reaction; bp,
base pair(s).
TABLE I
S. cerevisiae strains used in the study
Differences in the genotype from the parental strains are indicated in the table.
Strain Deletion Genotype Source
W1021–7c a, ade2–1, can1–100, his3–11, 17, leu2–3, ura3–1 R. Rothstein
W1089–6c a, ade2–1, can1–100, his3–11, 17, trp1–1, ura3–1 R. Rothstein
AB15Ba a, ade2–1, can1–100, his3–11, 17, leu2–1, trp1–1, ura3–1 This work
AB15Baa Genotype of AB15B 1 PDB This work
AB15Bba Genotype of AB15B 1 PDB-ScEXO1 This work
AB15Bca Genotype of AB15B 1 PDB-hEXO1 This work
HUWTa a, his3-Dhis3::URA3::Dhis3 This work
HUWTaa Genotype of HUWT 1 PRS314-ADH1 This work
HUWTba Genotype of HUWT 1 PRS314-ADH1-ScEXO1 This work
HUWTca Genotype of HUWT 1 PRS314-ADH1-hEXO1 This work
AB15Da EXO1 a, exo1::URA3 This work
AB15Daa EXO1 Genotype of AB15D 1 PRS314-ADH1 This work
AB15Dba EXO1 Genotype of AB15D 1 PRS314-ADH1-ScEXO1 This work
AB15Dca EXO1 Genotype of AB15D 1 PRS314-ADH1-hEXO1 This work
HUWT1a EXO1 a, his3-Dhis3::URA3::Dhis3, exo1:hisG This work
HUWT1aa EXO1 Genotype of HUWT1 1 PRS314-ADH1 This work
HUWT1ba EXO1 Genotype of HUWT1 1 PRS314-ADH1-ScEXO1 This work
HUWT1ca EXO1 Genotype of HUWT1 1 PRS314-ADH1-hEXO1 This work
FDERa EXO1&RAD51 a, exo1::URA3, rad51::LEU2 This work
FDERaa EXO1&RAD51 Genotype of FDER 1 PRS314-ADH1 This work
FDERba EXO1&RAD51 Genotype of FDER 1 PRS314-ADH1-ScEXO1 This work
FDERca EXO1&RAD51 Genotype of FDER 1 PRS314-ADH1-hEXO1 This work
IC2–1a RAD27 a, rad27::LEU2 This work
IC2–1aa RAD27 Genotype of IC1–2 1 PDB This work
IC2–1ba RAD27 Genotype of IC1–2 1 PDB-ScEXO1 This work
IC2–1ca RAD27 Genotype of IC1–2 1 PDB-hEXO1 This work
U687a RAD51 a, rad51::LEU2 A. Bailis
U687aa RAD51 Genotype of U687 1 PRS314-ADH1 This work
U687ba RAD51 Genotype of U687 1 PRS314-ADH1-ScEXO1 This work
U687ca RAD51 Genotype of U687 1 PRS314-ADH1-hEXO1 This work
RKY2672 a, ade2–1, ade8, hom3–10, his3–200, 17, leu2–1, lys2DBgl, trp1–63, ura3–52 R. D. Kolodner
RKY2672a Genotype of RKY2672 1 PRS314-ADH1 This work
RKY2672b Genotype of RKY2672 1 PRS314-ADH1-ScEXO1 This work
RKY2672c Genotype of RKY2672 1 PRS314-ADH1-hEXO1 This work
MEXO1b EXO1 a, exo1::LEU2 This work
MEXO1ab EXO1 Genotype of MEXO1 1 PRS314-ADH1 This work
MEXO1bb EXO1 Genotype of MEXO1 1 PRS314-ADH1-ScEXO1 This work
MEXO1cb EXO1 Genotype of MEXO1 1 PRS314-ADH1-hEXO1 This work
a The strains are derivatives of W1021–7c and W1089–6c.
b The strains are derivatives of RKY2672.
Functional Complementation of Human Exonuclease 1 in Yeast17894
used to confirm the deletion of RAD27 gene by PCR: RAD27F (AAAC-
GCGACGCGTAACATCG) and RAD27R (ATATGCCAAGGTGAAGGA-
CC). Null mutant strains of RAD51 and RAD51/EXO1 were from
laboratory stock (51).
Complementation of ScEXO1 and HEX1 in S. cerevisiae—Two vec-
tors, pDB20 and pRS314, were used for the expression of EXO1 in S.
cerevisiae. pDB20 is a URA3 and ADH1 promoter-based yeast expres-
sion vector. Two plasmids, PDB-ScE and PDB-hE, were constructed to
express Sc- and h- exonuclease 1 in S. cerevisiae. PDB-ScE has an
insertion of S. cerevisiae EXO1 (ScEXO1) at the HindIII site of pDB20
while PDB-hE has an insertion of human EXO1 (hEXO1) at the NotI
site of pDB20. pRS314 is a yeast subclone vector using TRP 1 as a
selection marker. PRS-ScE and PRS-hE were constructed to comple-
ment the exonuclease 1 function in the rad27::URA3 background. PRS-
ScE has an insertion of Padh-ScEXO1-Tadh (Padh, ADH 1 promoter;
Tadh, ADH1 terminator) at SacI and ApaI sites. PRS-hE has an inser-
tion of Padh-hEXO1-Tadh at BamHI site. The plasmids were trans-
formed into different S. cerevisiae strains for exonuclease 1 functional
complementation as listed in Table I.
Overexpression and Purification of hExo1—Full-length human EXO1
coding sequence was subcloned into pET-28a vector (Novagen) using
the cDNA clone harboring hEXO1 and PCR primers 5exo1 and 3exo1
containing NheI and SalI sites (5exo1, GACTGTGCTAGCATGGGGA-
TACAGGGATTG and 3exo1, TGTCACTGTCGACAATCCAAAGTTTT-
TCCAG), respectively, yielding pET-HEX. Both pET-28a and pET-HEX
were transformed into BL21 (DE3) cells (Novagen). Colonies were inoc-
ulated into 50 ml of LB broth supplemented with 30 mg/ml kanamycin
and cultured overnight. The culture was pelleted and transferred in 4 3
1-liter of sorbitol medium (54). Cultures were grown at 37 °C to OD 0.6
followed by induction at 25 °C with 1 mM isopropyl-b-D-thiogalactoside
for 4 h. The cells were harvested and stored at 280 °C until use. All of
the purification steps were performed at 4 °C. The cells was thawed in
a mixture of ice and water and resuspended in buffer A (20 mM
Na2HPO4, pH 7.9, 0.5 NaCl) with 10 mM imidazole. Cells were sonicated
and the lysate was then centrifuged at 17,000 rpm for 45 min to remove
cell debris. A 5-ml HiTrap Chelating Ni21 column was equilibrated with
buffer A using Fast Protein Liquid Chromatography system (Pharma-
cia). After loading, the column was washed with 25 ml of buffer A with
10 mM imidazole, 25 ml of buffer A with 60 mM imidazole, and then
eluted with a 50-ml linear gradient from 60 to 500 mM imidazole in
buffer A at 2 ml/min. The fractions were run on the 10% SDS-polyac-
rylamide gel and stained with Coomassie Brilliant Blue R-250 to visu-
alize the purity of protein. Buffers of the fractions were exchanged to 10
mM Tris, 150 mM NaCl, pH 8.0, by HiTrap desalting column (Pharma-
cia). Protein concentrations were determined using the Bio-Rad protein
assay.
Nuclease Activity Assay—To prepare substrates for ribonuclease ac-
tivity assays, an upstream primer (59-TTTTATAACTCGGAGAGCCG-
TAATG-39, the bold nucleotides are the 59 single-stranded portion of
exonuclease 1 substrates) and a 59-labeled 21-ribonucleotide/30-de-
oxyribonucleotide junction oligo (59-gggaacaaaagcuugcaugccTGCAG-
GTCGACTCTAGAGGATCCCCGGGTA-39, the lowercase indicates the
ribonucleotides) were annealed to the 76-mer template (59-TTTTTAC-
CCGGGGATCCTCTAGAGTCGACCTGCAGGCATGCAAGCTTTTGT-
TCCCCATTACGGCTCTCCGAGTTAT-39) resulting in a Okazaki frag-
ment-like substrate (ribo-substrate-1). To test the ability of human
exonuclease 1 in removal of the last ribonucleotide attached to DNA,
59-labeled mono-ribonucleotide/30-deoxynucleotide junction oligo (59-
cTGCAGGTCGACTCTAGAGGATCCCCGGGTA-39) were annealed to a
55-mer complementary strand (59-TTTTTACCCGGGGATCCTCTAGA-
GTCGACCTGCAGTAGACGTCTGACACAGCCGT-39) to form a nicked
duplex substrate (ribo-substrate-2). An upstream primer (59-TTTTAC-
GGCTGTGTCAGACGTCTA-39) has also been added to the above sub-
strate (ribo-substrate-2) to form the ribo-substrate-3. Furthermore, a 59
end-labeled oligo (59-ACGGCTGTGTCAGACGTCTACTGAGGTCGAC-
TCTAGAGGATCCCCGGGTA-39) was annealed to the template strand
of the ribo-substrate-2 to form blunt end double-stranded DNA as a
substrate for a 59 DNA exonuclease activity assay. Based on the
property that hExo 1 has a negligible activity on a single-stranded
DNA, all unlabeled 59 ends of the substrates have four additional nu-
cleotides to form the single-stranded ends and block the enzyme activity.
The ribonuclease reactions were performed as described previously (55).
Briefly, a standard reaction mixture contained 0.8 pmol of [g-32P]nu-
cleic acid substrate, 50 mM Tris-HCl, pH 8.0, 10 mM MgCl2, and 10 ng
of enzyme in 13 ml and were incubated at 33 °C for 30 min. The labeled
substrates were prepared in a concentration ratio of 1 labeled oligonu-
cleotide to 103-106 unlabeled oligonucleotide. The reactions were
stopped by adding an equal volume of stop solution (U. S. Biochemical
Corp.), mixed, boiled for 3 min, and cooled in ice. 3 ml of each reaction
product was run on a 15% denaturing polyacrylamide gel and exposed
to Kodak x-ray film for an image. For time-dependent kinetic analysis,
the cleavage reaction was stopped in different time points. The products
were resolved on a denaturing gel. Quantification of the band intensities
was done with a PhosphorImager (Stratagene, CA) and the computer
program IPLab Gel assay (Signal Analytics, VA).
Recombination Assay—The recombination assay was based on a
construct of URA3 gene flanked at both ends by the same DNA frag-
ment (413 bp) from the HIS3 gene direct repeats (see Fig. 2 and Ref. 56).
The construct was inserted into the HIS3 gene in the wild type S.
cerevisiae cells. These cells were hybridized with exo1 or rad27 null
mutants. They were then sporulated and dissected to produce the exo1
or rad27 null mutant strains with the assay construct. The strains were
cultured in the SD-URA medium to saturation. They were then plated
onto histidine minus SD (SD-HIS) medium. The optimal concentration
for plating was tested based on three different concentrations (5 3
concentrated, saturated, and 10 3 diluted). For the wild type and exo1
null mutants, 100 ml of saturated culture cells was optimal and plated
onto SD-HIS medium. After 3–4 days, HIS31 recombinant colonies
were counted and recombination rate was calculated by the number of
recombinants divided by the total number of viable cells.
UV Sensitivity Analysis—Analysis was carried out as described pre-
viously (51) except that the strains in this study were transformed with
plasmids, pRS314, pRS-ScE, or pRS-hE, respectively (Table I). Strains
were grown in tryptophan minus SD (SD-TRP) liquid to saturation at
30 °C and cell density was measured with a spectrophotometer (600
nm), diluted in water, and plated on SD-TRP agar plate. The plates
were exposed to different UV dosages (254 nm germicidal lamp) and
incubated in the dark for 3–4 days at 30 °C before colonies were
counted. Survival rate was determined based on the ratio between
colony counts with and without UV treatment. Survival curves repre-
sent the average from at least six independent experiments.
Suppression Analysis—The pDB overexpression vector with or with-
out insertion of either HEX1 or ScEXO1 was transformed into the
rad27 null mutant and wild type strain of S. cerevisiae. To observe
colony growth, the transformants were streaked onto the SD-URA
medium side by side with duplications. They were incubated at 37 and
30 °C, respectively. The transformants were also cultured in the SD-
URA liquid medium to saturation to measure the growth curve. The
saturated cultures were then normalized and inoculated in 10 ml of
SD-URA liquid medium. The growth was determined using a spectro-
photometer in different time intervals for the curve.
Mutator Phenotype Analysis—To observe the role of EXO1 in muta-
tion avoidance, the mutator phenotype of exo1 deletion mutant (exo1)
and the ones transformed with ScEXO1 and HEX1 were determined
using an assay based on cycloheximide resistance (57). The strains were
cultured to saturation in 2.5 ml of SD-TRP liquid medium. For control,
0.2 ml of the culture was diluted by 1 ml of distilled water and 50 ml of
the diluted samples was plated onto the SD-TRP agar plate for cell
number counting. The remaining samples were spun down and plated
onto the SD-TRP agar plate with 10 mg/liter cycloheximide. Mutation
rate for each strain was calculated from six independent experiments.
RESULTS
Protein Sequence Comparison Predicted That Human Exo-
nuclease-1 Is a Yeast Functional Homolog—A cDNA clone
(number 843301) harboring a putative human exonuclease 1
was obtained from ATCC. Sequence of cloned cDNA was deter-
mined in our laboratory and deposited in GenBank (accession
number AF060479) and translated into the protein sequence.
Sequence of S. cerevisiae exonuclease 1 was obtained from the
NCBI protein data base. They were then aligned using Optimal
Global Alignment of Two Sequences at EERIE (Nimes, France)
(Fig. 1). Overall sequence identity and similarity between hu-
man and S. cerevisiae EXO1s are 27 and 55%, respectively. The
identity and similarity between the putative nuclease domains
of the yeast Exo1 and Rad27 nuclease in are 28 and 57%. High
sequence conservation between the human and S. cerevisiae
predicts that they are functional homologs and leads us to test
in yeast if the human enzyme can complement the character-
ized functions of the yeast enzyme.
Expression of HEX1 Restores the Recombination Rate in an
exo1D Strain—ScEXO1 is involved in spontaneous mitotic and
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meiotic recombination between direct repeats (45, 47). Comple-
mentation of this function during S. cerevisiae mitotic growth
by HEX1 was determined by measuring the rate of recombina-
tion between nontandem direct repeats of the HIS3 genes (Fig.
2). The two HIS3 alleles are truncated at their 39 and 59 ends,
respectively, and are separated by plasmid vector sequences
including the URA3 gene. The end repeats of the HIS3 gene in
this system are 413 bp in length. Strains containing this du-
plication form can grow on the SD medium without uracil.
Recombination events that excise the DNA between the repeats
and restore the HIS3 gene are visualized as the recombinant
cells can grow on the medium without histidine. Recombination
rate in a strain containing this direct repeat and a disruption of
the EXO1 gene were 58% lower than that of the wild type
strain hosting the HIS3 gene construct as a control. Expression
of either ScEXO1 or HEX1 restored the recombination rate to
the wild type level as shown in Table II.
Expression of HEX1 Ablates the UV Sensitivity of an exo1D
Strain—Deletion of the EXO1 gene in S. cerevisiae causes a
minor UV sensitivity (51). Epistatic analysis indicated that the
observed phenotype was not due to the defective RAD2-depend-
ent nucleotide excision repair or loss of its known function in
RAD51-dependent double strand break-induced recombination
pathway or mismatch repair pathway. It is most likely due to
its involvement in a DNA replication by-pass pathway. Double
deletion of EXO1 and RAD51 made the strain very sensitive to
UV treatment. Introduction of the human and yeast EXO1
expression plasmids into this double deletion mutant strain
recovered the UV sensitivity close to the level of the rad51D
mutant (Fig. 3).
Purified hExo1 Efficiently Removes RNA Primers from Oka-
zaki Fragment Model Substrates—Full-length human exo-
nucleases-1 cDNA was cloned into the pET28a vector and ex-
pressed in E. coli using sorbitol medium as described
previously (54, 58). PCR primers were designed to add both N-
and C-terminal His tags onto the recombinant protein. The
final products of fast protein liquid chromatography purifica-
tion using a nickel affinity column contained two protein bands
(approximately 93 and 45 kDa). Microsequencing of both
polypeptides revealed the expected N-terminal sequence of the
human exonuclease 1 deduced from its cDNA sequence
(MGIQGLL). Therefore, the smaller polypeptide is a C-termi-
FIG. 2. A recombination assay used in this study. The yeast
strain, HUWT (wild type) and HUWT1 (exo1D), containing a recombi-
nation substrate on the chromosome that consists of two nontandem
direct repeats of truncated alleles (415 bp) of the his3 gene separated by
the URA3 sequence were used in this experiment. They were trans-
formed with three plasmids: PRS314, PRS-ScE, and PRS-hE to meas-
ure the complementation ability of HEX1 in recombination (see the
results in Table II).
TABLE II
His1 recombination frequency in strains containing the
his2–39D::URA3::his3–59D
Strains Genotype
Recombinants
per 104 viable
cells
Relative
frequency
%
HUWTa Wild type/pRS314 2.65 6 0.44 100
HUWT1a exo1/pRS314 1.12 6 0.23 42
HUWT1b exo1/PRS-ScE 2.55 6 0.29 96
HUWT1c exo1/PRS-hE 2.16 6 0.31 82
FIG. 1. Sequence alignment of
hExo1, ScExo1, and the putative nu-
clease domain of ScRad27.P indicates
identical amino acids; : indicates similar
amino acids; and * the conserved amino
acids composing a nuclease active site as
demonstrated in crystallography and site-
directed mutagenic experiments of homol-
ogous enzymes of FEN-1 (61, 62). Overall
sequence identity and similarity between
human and S. cerevisiae EXO1s are 27
and 55%, respectively. Underlined are the
conserved regions between exonuclease 1
and Rad27 nuclease.
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nal degradation product of the 93-kDa protein. All of the Exo1
homologs (S. cerevisiae, S. pombe, and human) possess a 59-39
double-stranded DNA exonuclease activity. To explore the pos-
sibility that the enzyme might participate in RNA primer re-
moval during eukaryotic DNA replication lagging strand DNA
synthesis, three Okazaki fragment model substrates were pre-
pared as ribo-substrates-1, -2, and -3 (Fig. 4) that mimic dy-
namic lagging strand DNA replication intermediates. Indeed,
the enzyme possesses a 59 riboexonuclease activity on all of the
substrates. A blunt ended double-stranded DNA duplex was
included as a control (Fig. 4, A-D). The time course of the
enzyme reaction indicates that the reactive efficiency of the
enzyme with ribo-substrate-1, -2, and double-stranded DNA
substrate are similar (Fig. 5, A-D). hExo1 digests both RNA
and DNA with a duplex substrate with or without an upstream
primer. However, the enzyme releases mononucleotides with
the substrate-1, -2, and DNA duplex while it cleaves mono-, di-,
and trinucleotides simultaneously from the 59 end with sub-
strate-3 (an upstream primer was added to the substrate-2,
Fig. 4C).
Expression of Both ScEXO1 and HEX1 Suppressed the Le-
thality of rad27D Mutant at 37 °C—Yeast Rad27 nuclease and
its mammalian homolog FEN-1 functions in RNA primer re-
moval during lagging strand DNA synthesis (29, 38, 43). rad27
null mutants displayed a conditional lethality phenotype: the
cells grow slowly at 30 °C but were arrested in S-phase at
37 °C. The mutants also have a hyper-recombination pheno-
type. This is indicative of long-lived regions of single-stranded
DNA in the chromosome and is symptomatic of a defect in
Okazaki fragment processing. A partial defect in this process
indicates that an inefficient nuclease backs up the function of
the Rad27 nuclease. Exonuclease-1 shares a conserved nucle-
ase domain with the Rad27 nuclease (Fig. 1). Deletion of both
EXO1 and RAD27 in S. cerevisiae leads to complete lethality of
cells (data not shown). Expression of ScEXO1 and HEX1 in a
rad27 null mutant promotes the colony formation at 37 °C even
though the human gene has less capacity to remove RNA
primers in yeast as the transformants formed smaller colonies
(Fig. 6). All of these strains were grown in the liquid YPD
medium at 37 °C to determine the growth curve. The results
indicated that the expression of both Sc- and human EXO1
gene made the rad27 null mutant grow more closely to the wild
type even though the strain harboring the human EXO1 gene
grew more slowly than the rad27D mutant with the ScEXO1
(Fig. 7).
Expression of Both ScEXO1 and HEX1 Reversed the Mutator
Phenotypes—Due to the functions of the EXO1 gene in recom-
binational mismatch correction and probably in RNA primer
removal, deletion of the gene increased yeast mutation rates
29-fold in the cycloheximide resistance assay (Table III). The
rate increased about 6-fold in the CANr and HOM assays (59).
Expression of both ScEXO1 and HEX1 reversed the mutator
phenotypes of an exo1 null mutant and the mutation rate was
reduced to the wild type level. These data indicate that the
human gene is a functional homolog of the yeast gene and can
play a role in mutation avoidance in heterogeneous cellular
environment.
FIG. 3. UV sensitivity of S. cerevisiae exo1 null mutatnt is re-
versed by the expression of Sc- or h-EXO1. As revealed previously
(51), the single deletion of S. cerevisiae EXO1 only exhibits a minor UV
sensitivity whereas the double deletion of EXO1 and RAD51 has a
synergistic effect. For this reason, the double deletion mutant was used
to test if the HEX1 could complement the function of S. cerevisiae EXO1
in the UV DNA damage repair. l, AB15Be (wt/pRS 314); M, AB1Ba
(exo1D/pRS314); D, U687a (rad51D/pRS314); E, FDERa (exo1Drad51D/
pRS314); , FDERb (exo1Drad51D/PRS-ScE); l, FDERc (exo1Drad51D/
PRS-hE). The data was averaged from six independent experiments.
FIG. 4. The purified Exo1 protein shows the 5*-3* double strand
exonuclease activity and 5*-3* riboexonuclease activity. Exonu-
clease activity of human recombinant Exo1 was tested with a blunt
ended DNA duplex substrate and illustrated in panel D. The 59-39
riboexonuclease activities were tested with Okazaki fragment-like sub-
strates and illustrated in panels A-C. Sequence of oligoes used to make
the substrates is given in the text. The assays were performed as
described under “Experimental Procedures.” Time points were 0, 1, 1.5,
2.5, 5, 7.5, 10, and 20 min. Lanes 1–8, triangles denote increasing
reaction time. Dots in the substrate scheme represent RNA portion. The
filled dots indicate the 59 single strand blockage to the 59 Exo1 activity.
Arrows with nt (nucleotide) show the length of the substrates and
products; * indicates the radioactively labeling position.
Functional Complementation of Human Exonuclease 1 in Yeast 17897
DISCUSSION
Sequence and in Vitro Functional Conservation of Eukaryotic
59-Exonuclease 1—The enzyme has so far been identified in S.
pombe, S. cerevisiae, D. melanogaster, and human (44–52).
Sequence similarity of Exo1s from these eukaryotic organisms
indicates evolutionary and functional conservation of this im-
portant group of 59-exonucleases. The biochemical properties of
hExo1 are similar to that of ScExo1. The enzyme is a non-
processive 59-39 double-stranded and single-stranded DNA ex-
onuclease. In S. cerevisiae, the 59-39 exonuclease activity is
2-fold more on double-stranded DNA than on single-stranded
DNA. The purified protein from S. pombe, however, has very
low 59-39 single-stranded DNA exonuclease activity. It is more
specific for the double-stranded DNA. It is possible that the
truncated protein purified from S. pombe lacks a structure
responsible for 59-39 single strand DNA exonuclease activity.
Resembling the ScExo1, human exonuclease 1 has both activ-
ities but prefers a double-stranded DNA substrate to single-
stranded DNA. However, it does not discriminate between
RNA and DNA (Fig. 4 and see below). Because the observed
sequence conservation of the putative nuclease domains be-
tween the exonuclease-1 and flap endonuclease-1 (see Refs. 28,
29, 60, and 62 for additional information on FEN-1 nuclease),
we tested the flap endonuclease activities of human exonucle-
ase-1 with a typical flap DNA substrate with DNA or RNA as
the single-stranded portion and human flap endonuclease-1 as
a positive control. The result indicates that the enzyme does
not possess a specific flap endonuclease activity. A detailed
description of the human exonuclease 1 substrate specificity
will be published elsewhere.
Human Exonuclease 1 Functionally Complements the Yeast
DNA Recombination and UV Resistance and Mutation Avoid-
ance—Expression of human exonuclease 1 in yeast comple-
ments several characterized phenotypes in the exo1D mutants.
hExo1 complements the function of ScExo1 in recombination
(Table II). The recombinational rate decreases 2-fold when the
EXO1 gene was deleted in our assay system, where the repeat
fragments were about 400 bp. 7-fold decrease was reported
when the repeats were extended to 900 bp (45). It was also
demonstrated in vitro that the enzyme significantly promotes
the recombination of the two DNA fragments with end over-
lapping sequence. As revealed in S. pombe, mRNA level and
enzyme activity was induced during meiosis (44, 45) and in D.
melanogaster, it is only expressed in the early embryogenesis of
the female germline (46). We speculate that the functional
59-exonuclease 1 may be involved in recombinational mismatch
correction during meiosis in mammalian cells as no such eu-
karyotic enzyme has been identified to date.
In S. cerevisiae, it has been shown that Exo1 is involved in
UV DNA damage repair, which is distinct from nucleotide
excision repair pathway (49). In this study, we revealed that
hEXO1 complements the function of ScExo1 in UV DNA dam-
age repair, indicating that hExo1 could be involved in UV DNA
damage repair in human cells as well. Among the different UV
FIG. 5. Human exonuclease 1-driven
reactions with three different RNA-
DNA/DNA and DNA/DNA duplex sub-
strates. The reactions have been con-
ducted under the conditions described in
the legend to Fig. 4 and under “Experimen-
tal Procedures” with excessive substrate to
the enzyme. 103-106-fold more of unlabeled
oligoes than the labeled oligo were used to
construct the substrates. Densitometry
was used to quantify the conversion of sub-
strate to product. A, reaction with blunt
ended double-stranded DNA substrate; B,
reaction with RNA-DNA/DNA substrate
(ribo-substrate-1); C, reaction with monori-
bonucleotide-DNA/DNA substrate (ribo-
substrate-2); D, superimposition of A, B,
and C. The data is from the average of
three independent experiments.
FIG. 6. Overexpression of Sc- or h-Exols suppresses the lethal-
ity of RAD27/FEN-1 mutant at 37 °C. Wild type (wt) and rad27
mutant (IC2) strains were grown on the SD-URA plate with and with-
out the introduction of Sc- and h-EXO1s. a, AB15Ba (wt/pDB20); b,
AB15Bb (wt/PDB-ScE); c, AB15Bc (wt/PDB-hE); d, IC2-1c (rad27/PDB-
hE); e, IC2-1b (rad27D/PDB-ScE); f, IC2-1a (rad27D/PDB20).
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DNA damage repair pathways, the XPG/Rad2 nucleotide exci-
sion repair pathway is a major pathway. In humans, dysfunc-
tion of this repair pathway results in xeroderma pigmentosum
syndrome. Epistatic analysis in yeast showed that the UV DNA
damage repair involving Exo1 is independent of XPG/Rad2
nucleotide excision repair and other UV DNA damage repair
pathways (51). The minor UV sensitivity is due to the failure of
DNA replication-driven bypass compensation mechanism.
Failure of mismatch correction during DNA recombinational
repair increases mutation rate. Deletion of ScEXO1 caused a
29-fold increase in cycloheximide resistance in S. cerevisiae.
The assay is based on the fact that mutation in the yeast gene
CYH2 can lead to resistance to cycloheximide, an inhibitor of
eukaryotic protein synthesis. The gene product of CYH2 is
ribosomal protein L29, a component of the 60 S ribosomal
subunit. In most cases, resistance to cycloheximide is due to a
transversion mutation resulting in replacement of a glutamine
by a glutamic acid in position 37 of Leu-29 (57). Mutation rates
in a ScEXO1 deletion mutants assayed with another system
such as CANr and HOM3 are only increased 6-fold compared
with wild type (59). The different mutation rates determined
may be due to the following reasons: 1) the CANr assay is a
forward assay but not particularly sensitive to the point muta-
tions such as transversions; 2) the HOM3 assay is sensitive to
single base deletions and additions, which happens frequently
in mismatch repair defective cells. This is a reversion assay.
The mutant strain causes at a high rate the deletion of a single
T in a run of 7 Ts. Otherwise, the HOM3 protein does not
tolerate much sequence variation elsewhere. Table III also
shows that HEX1 complements the function of ScExo1 and
reverses the mutator phenotype in exo1D mutants. This result
implies that hExo1 could play a role in the mutation avoidance
mechanism in human cells. The result is also consistent with
the role of exo1 in mismatch correction in S. pombe (44). The
protein interacts with Msh2 (48, 49) and double knockout of
EXO1 and MSH2 showed the similar mutation rate as the
single knockout of MSH2. Altogether, the evidence available
indicates that these two proteins may work together in a mu-
tation avoidance mechanism.
Human Exonuclease 1 Backs Up the Function of Flap Endo-
nuclease 1 in DNA Replication RNA Primer Removal—Fig. 4
shows a time-dependent ribonuclease activity of hExo1 on
RNA/DNA hybrid duplexed to a DNA template regardless of
multiple or monoribonucleotide proceeding the DNA portion.
This activity may indicate the involvement of Exo1 in RNA
primer removal during lagging strand DNA synthesis. In pro-
karyotes, the role of RNA primer removal during DNA lagging
strand synthesis is played by the 59-39 exonuclease activity of
DNA polymerase I (24–27). In eukaryotes, the function of re-
moving RNA primers of the lagging DNA strand is performed
by the FEN-1/Rad27 nuclease in two alternative pathways.
One pathway is that RNase H removes all ribonucleotides
except for the last one adjunct to DNA fragments; then, the last
ribonucleotide is removed by FEN-1/Rad27 nuclease. The sec-
ond pathway is performed by FEN-1/Rad27 nuclease via its
flap endonuclease activity independent of RNase H. If there are
only these two pathways involved in the removal of the RNA
primers, disruption of the FEN-1/RAD27 gene in yeast should
completely block the RNA primer removal pathways and the
null mutant may be lethal. However, disruption of ScRAD27
caused a conditional lethality phenotype (39–42): the null mu-
tant cells could still grow at the normal temperature (30 °C)
but become lethal at 37 °C. For this reason, a third pathway for
removing RNA primers has been proposed (29) and Exo1 is one
of the best candidates for this pathway due to its 59-39 exonu-
clease activity. The hExo1 was as efficient in removal of ribo-
nucleotides as deoxynucleotides, resembling the function of
Rad27 in RNA primer removal pathway in our experiments. As
we have also shown, the overexpression of HEX1 as well as
ScEXO1 in yeast S. cerevisiae cells suppressed the tempera-
ture-sensitive phenotype of rad27/fen-1 null mutant at 37 °C.
This result indicates that the Exo1 enzyme is involved in re-
moval of RNA primers during lagging strand DNA synthesis.
Bambara’s hypothesis (29) on the candidate nucleases for ini-
TABLE III
Expression of hEXO1 reverses cycloheximide resistance of the exo1
null Saccharomyces cerevisiae
Strains Genotype
Mutation
frequency (3
1028)
Relative
rate
AB15Be Wild type/pRS314 0.22 6 0.05 1
AB1Ba exo1/pRS314 6.21 6 0.81 29
AB1Bb exo1/PRS-ScE 0.28 6 0.09 1.3
AB1Bc exo1/PRS-hE 1.12 6 0.21 5.1
FIG. 7. Cell growth curve of rad27
mutant strain with and without the
introduction of Sc- and hEXOls. Cells
were grown in SD-URA liquid medium at
37 °C starting with the same amount of
initial culture. Samples were taken in ev-
ery 2–3-h time intervals to measure the
OD units. The data were averaged from
three independent experiments. L,
AB15Ba (wt/pDB20); M, AB15Bb (wt/
PDB-ScE); D, AB15Bc (wt/PDB-hE); *,
IC2-1a (rad27D/PDB20); E, IC2-1b (rad27D/
PDB-ScE); 3, IC2-1c (rad27/PDB-hE).
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tiator RNA removal is supported by the fact that overexpres-
sion of EXO1 suppresses the temperature-sensitive phenotype
of rad27/fen-1 null mutant at 37 °C and the lethality of the
double knockout of RAD27 and EXO1 (48).
Recently, however, it has also been proposed that the unli-
gated Okazaki fragments of the rad27 null mutant can also be
repaired by the recombinational double strand break repair
pathway (43). This hypothesis is based on the fact the disrup-
tion of FEN-1/RAD27 can elevate recombination rate by 20–
30-fold (43).2 In addition, the double knockout of RAD27 and
RAD51 or RAD52 (the key protein components of double strand
break repair) is lethal. The double strand break repair pathway
requires 59-39 exonuclease to generate the single-stranded 39-
overhangs for strand invasion. EXO1 is a good candidate for
this process as well. Meanwhile, if EXO1 is the only enzyme so
far available, which possibly generates the single-stranded 39-
overhangs in a eukaryotic cell, deletion of EXO1 would block
the double strand DNA break repair pathway. The double
knockout of RAD27 and EXO1 would result in the cell lethality
as that of RAD27 and RAD51 or RAD52. This hypothesis is
supported by the fact that the knockout of EXO1 reduced
recombination rate and the double knockout of RAD27 and
EXO1 is indeed lethal. However, this hypothesis does not ex-
plain the result that the overexpression of EXO1 suppressed
the temperature-sensitive phenotype of rad27 null mutant un-
less the overexpression of Exo1 facilitates an alternative proc-
ess for the RNA primer removal. With the above information in
mind, we propose that Exo1 might be involved in two pathways
relevant to DNA replication. On one hand, it could back up the
function of FEN-1 to remove RNA primers; on the other hand,
it is involved in the double strand DNA break repair pathway
to generate 39-overhang, correct the mismatches, and remove
unligated Okazaki fragments in the rad27 mutant.
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